Biocomposites

Executive Summary

Biocomposites is a UK-based medical device company specializing in calcium-based biomaterials for bone regeneration and infection treatment. Founded in 1995, the company has developed a portfolio of products including antibiotic-loaded calcium sulfate, synthetic bone grafts, and bone cements, targeting musculoskeletal infections, trauma, and revision surgeries. With over 25 years of experience, Biocomposites has established itself as a niche player in the orthobiologics space, leveraging its proprietary calcium technology to address challenging clinical needs. The company's products are designed to deliver local antibiotics while promoting bone healing, offering a unique solution for osteomyelitis and infected non-unions. Biocomposites operates in a growing market driven by an aging population and increasing incidence of orthopedic infections, positioning it for continued expansion. Biocomposites has a track record of innovation and clinical adoption, with its products used in over 30 countries. The company is privately held and continues to invest in R&D to expand its product line and indications. Key areas of focus include developing next-generation synthetic bone grafts and combination products for enhanced infection control. With a strong IP portfolio and regulatory clearances in major markets, Biocomposites is well-positioned to capture share in the global orthopedic biomaterials market. The company's conviction score is 75, reflecting its established commercial presence and growth potential within a specialized segment.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval for Next-Generation Antibiotic-Loaded Calcium Sulfate80% success
• Q4 2026Partnership for Distribution in Asia Pacific Region65% success
• Q1 2027Publication of Clinical Data for Synthetic Bone Graft in Spinal Fusion70% success